IL6 and cervical cancer: Therefore, in this study, TAMs with PD-1 monoclonal antibodies can promote the expression of t-SHP2, inhibiting the relative protein expression of IL-6, IL-4, IL-10, PD-L1, XBP-1, and cathepsin K. Moreover, TAMs with PD-1 monoclonal antibodies can inhibit the migration ability of cervical cancer cells.